

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>Date Submitted: November 13, 2002 (use as many sheets as necessary)</p>				<p>Complete If Known</p> <table border="1"> <tr> <td>Application Number</td> <td>09/258,882</td> <td>10/6/04</td> </tr> <tr> <td>Filing Date</td> <td>03/01/1999</td> <td>NOV 04 2003</td> </tr> <tr> <td>First Named Inventor</td> <td colspan="2">Linda D. ARTMAN et al.</td> </tr> <tr> <td>Group Art Unit</td> <td colspan="2">1614</td> </tr> <tr> <td>Examiner Name</td> <td colspan="2">Shep K. Rose</td> </tr> <tr> <td>Attorney Docket Number</td> <td colspan="2">085747-0139</td> </tr> </table>		Application Number	09/258,882	10/6/04	Filing Date	03/01/1999	NOV 04 2003	First Named Inventor	Linda D. ARTMAN et al.		Group Art Unit	1614		Examiner Name	Shep K. Rose		Attorney Docket Number	085747-0139	
Application Number	09/258,882	10/6/04																					
Filing Date	03/01/1999	NOV 04 2003																					
First Named Inventor	Linda D. ARTMAN et al.																						
Group Art Unit	1614																						
Examiner Name	Shep K. Rose																						
Attorney Docket Number	085747-0139																						
Sheet	1	of	3																				

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

SEARCHED LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
	A1	JULIUS A. VIDA "Advances in Anticonvulsant Drug Development"; <i>Anticonvulsants</i> (1977) pp. 1-9; Academic Press.
	A2	JULIUS A. VIDA "Noncyclic Anticonvulsants"; <i>Anticonvulsants</i> (1977) pp. 577-619; Academic Press.
	A3	SALIM HADAD, et al. "Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine"; <i>Pharmaceutical Research</i> (1995), pp. 905-907; Plenum Publishing Corporation
	A4	ABDULLA HAJ-YEHIA, et al. "Structure-Pharmacokinetic Relationships in a Series of Short Fatty Acid Amides that Possess Anticonvulsant Activity"; <i>Journal Of Pharmaceutical Sciences</i> ; (August 1990); pp. 719-724; Vol. 79, No. 8.
	A5	ABDULLA HAJ-YEHIA, et al. "Pharmacokinetic Analysis of the Structural Requirements for Forming "Stable" Analogues of Valpromide"; <i>Pharmaceutical Research</i> ; (1992) pp. 1058-1063; Vol. 9, No. 8; Plenum Publishing Corporation.

Examiner Signature		Date Considered	6/14/14
-----------------------	---	--------------------	---------


***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for Form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	80/258,982 10/6/1999
Date Submitted: November 13, 2002				Filing Date	03/01/1999
(use as many sheets as necessary)				First Named Inventor	Linda D. ARTMAN et al. NOV 04 2003
Sheet	2	of	3	Group Art Unit	1614
				Examiner Name	Shep K. Rose
				Attorney Docket Number	085747-0139



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	A6	GEORGES TAILLANDIER, et al. "Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramifiés anticonvulsivants"; Eur. J. Med. Chem - Chemical Therapeutics; (September-October 1975 - 10); N° 5; pp. 453 - 462.			
	A7	JOEL G. HARDMAN, Ph.D., et al. "The Pharmacological Basis of Therapeutics" 10 th Edition; (2001)			
	A8	H. STEVE WHITE, et al. "Experimental Selection, Quantification, and Evaluation of Antiepileptic Drugs" ANTIEPILEPTIC DRUGS, Fourth Edition; (1995); pp. 99-110; Raven Press, New York.			
	A9	WALTER SNEADER "Drug Discovery: The Evolution of Modern Medicines" (1985), pp. 24-47; John Wiley & Sons			
	A10	JULIUS A. VIDA "Anticonvulsants"; Principles Of Modern Chemistry, 4 th Edition; (1995); pp. 182-198; Williams and Wilkins.			
	A11	DAVID A. WILLIAMS, et al. (Table of Contents) "Foye's Principles of Medicinal Chemistry" 5 th Edition (2002)			
	A12	W. LÖSCHER, et al. "Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation?" Epilepsy Research; (1994) pp. 95-134.			
	A13	A. HAJ-YEHIA, et al. "Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity" PMID: 2510141 [PubMed - Indexed for MEDLINE]			
	A14	A. HAJ-YEHIA, et al. "Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity" PMID: 2231336 [PubMed - Indexed for MEDLINE]			
	A15	ABDULLA HAJ-YEHIA, et al. "Structure-Pharmacokinetic Relationship in a Series of Valpromide Derivatives with Antiepileptic Activity"; Pharmaceutical Research; Vol. 6, No. 8, (1989) pp. 683-689; Plenum Publishing Corporation.			
	A16	HEINZ NAU, et al. "Pharmacologic Evaluation of Various Metabolites and Analogs of Valproic Acid: Teratogenic Potencies in Mice"; Fundamental And Applied Toxicology; 6, 669-676 (1986).			
	A17	P.E. KEANE, et al. "Effect of Valproate on Brain Gaba: Comparison with Various Medium Chain Fatty Acids"; Pharmacological Research Communications; Vol. 17, No. 6 (1985) pp. 547-555			
	A18	MEIR BAILER, et al. "Can We Develop Improved Derivatives of Valproic Acid?"; Pharmacy World Science (1994) 16(1) 2-6			
	A19	NINA ISOHERRANEN, et al. "Anticonvulsant Profile and Teratogenicity of N-methyl-tetramethylcyclopropyl Carboxamide: A New Antiepileptic Drug"; Epilepsia; Vol. 43, No. 2, pp. 115-126 (2002); Blackwell Publishing, Inc.			

Examiner Signature		Date Considered	6/04
--------------------	--	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/256,882 /D/614,244
Date Submitted: November 13, 2002		Filing Date	03/01/1999
(use as many sheets as necessary)		First Name Inventor	Linda D. ARTMAN et al.
Sheet	3	Group Art Unit	1614
	of	Examiner Name	Shep K. Rose
	3	Attorney Docket Number	085747-0139

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	6/04
-----------------------	---	--------------------	------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 085747/0139	SERIAL NO. 10/614,344 09/258,682		
<p>1 P</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>NOV 04 2003</p> <p>(Use several sheets if necessary)</p>		APPLICANT		Linda D. Artman et al.			
		FILING DATE		GROUP ART UNIT			
		March 1, 1999		1614			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
7	A1	3,485,851	12/23/69	Thiles	260	345.2	
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	A2	94/28888	12/22/94	WIPO			
	A3	97/34596	9/25/97	WIPO			
	A4	98/08498	3/5/98	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A5	P. E. Keane et al., "Effect of Valproate on Brain GABA: Comparison With Various Medium Chain Fatty Acids.", Pharmacological Research Communications, Italian Pharmacological Society, vol. 17, No. 6, June 1, 1985, pp. 547-555, XP-002049841					
	A6	Georges Taillandier et al., "Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramifiés anticonvulsivants.", European Journal of Medicinal Chemistry Chimica Therapeutica, FR, Editions Scientifique Elsevier, Paris, vol. 10, No. 5, September 1, 1975, pp. 453-462, XP-002049847					
EXAMINER		DATE CONSIDERED					6/04
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							



NOV 9 4 2013

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control
~~DUPLICATE FORM NUMBER~~

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>Date Submitted: March 19, 2002</p> <p>(use as many sheets as necessary)</p>				<p><i>Complete if Known</i></p> <table border="1"> <tr> <td>Application Number</td> <td>09/258,882</td> <td>10/614 344</td> </tr> <tr> <td>Filing Date</td> <td>03/01/1999</td> <td></td> </tr> <tr> <td>First Named Inventor</td> <td colspan="2">Linda D. ARTMAN et al.</td> </tr> <tr> <td>Group Art Unit</td> <td colspan="2">1614</td> </tr> <tr> <td>Examiner Name</td> <td colspan="2">Shep K. Rose</td> </tr> <tr> <td colspan="3">Attorney Docket Number</td> </tr> </table>		Application Number	09/258,882	10/614 344	Filing Date	03/01/1999		First Named Inventor	Linda D. ARTMAN et al.		Group Art Unit	1614		Examiner Name	Shep K. Rose		Attorney Docket Number		
Application Number	09/258,882	10/614 344																					
Filing Date	03/01/1999																						
First Named Inventor	Linda D. ARTMAN et al.																						
Group Art Unit	1614																						
Examiner Name	Shep K. Rose																						
Attorney Docket Number																							
Sheet	1	of	1	085747-0139																			

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁸
	C1	N. FURSAH et al., "VALEPOTRIATES OF SOME VALERIANACEAE BATSCH SPECIES AND PREPARING FORMULATIONS ON THE BASIS THEREOF," <u>Pharmacia</u> , Vol. 41, No. 5, pp. 69-74, 1992.	
	C2	V. DUNAEV et al., "BIOLOGICAL ACTIVITY OF THE SUM OF VALEIPOTRIATES ISOLATED FROM VALERIANA ALLIARIIFOLIA ADAMS," <u>Pharmacology and Toxicology</u> , No. 6, pp. 33-37, 1987.	


***EXAMINER:** Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the name of the source of the document.

Standard S1.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

10/6/14, 1344



Notice of References Cited

NOV 6 2003

Application No.

09/258882

Applicant(s)

ARTMAN, et al.

Examiner

S. Breyer

Group Art Unit

1614

Page ____ of ____

U.S. PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A	5 763 494	6/98	BALANDRIN, et al (II)	(6/11/93)	514 629
B	5 506 268	4/96	BALANDRIN, et al (I)	(6/11/93)	514 629
C	4 933 324	6/90	SHASHOVA (I)		514 17
D	4 939 174	7/90	SHASHOVA (II)		514 537
E	5 924 392	11/99	SHASHOVA (III)	(6/5/95)	514 437
F	6 107 499	8/00	SHASHOVA (IV)	(6/15/95)	514 78
G	6 258 836	7/01	SHASHOVA (V)	(to 9/4/90)	514 437
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N	94 2 8888 A	12/94	WO /PCT	Balandrin, et al (II)		
NO	98 084984	3/98	WO /PCT	artman, et al		
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

*	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U	USDA, A.R.S., DR. DUKK'S PHYTO CHEMICAL AND BOTANICAL DATABASES "CHEMICALS AND THEIR BIOLOGICAL ACTIVITIES IN: VALERIAN OPPICINENS - COMMON VALERIAN"	10/20/99
V		
W		
X		

* A copy of this reference is not being furnished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)

Part of Paper No. _____

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET

085747/0139

SERIAL NO.

09/258 882

APPLICANT

Linda D. Artman et al.

NOV 06 2003

(Use several sheets if necessary)

FILING DATE

3/01/1999

GROUP ART UNIT

1614

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,506,268	4/96	BALANDRIN et al.	514	629	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
	A2	94/28888	12/94	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A3	F. Fonnum, Biochemistry, Anatomy and Pharmacology of GABA Neurons", in Psychopharmacology the Third Generation of Progress, Raven Press, 1987, pp. 173-195.
	A4	J. M. Cedarbaum et al., "Drugs for Parkinson's Disease, Spasticity and Acute Muscle Spasms", in Goodman And Gilman's The Pharm. Basis of Thera., pp. 463-484, 1990.
	A5	J. W. Lance, Symposium synopsis in Spasticity – Disordered motor control, Feldman et al. (Eds), 1980, pp. 485-494.
	A6	R. Bernasconi et al., in Anticonvulsants in Affective Disorders, pp. 14-32, (Excerpta Medica 1984)
	A7	K. L. Casey, "Pain and Central Nervous System Disease: A Summary and Overview", in Pain and Central Nervous System Disease: The Central Pain Syndromes, Raven Press, 1991, pp. 1-11.
	A8	A. Danek et al., "Restless Legs Syndrome", Chapter 70, in Neurological Disorders: Course and Treatment, 1996, pp. 819-823.
	A9	P. D. Lyden, "GABA and Neuroprotection", Chapter 10, in Neuroprotective Agents and Cerebral Ischaemia, IRN 40, 1997, pp. 233-258.
	A10	W. A. Hauser, "Risk Factors for Epilepsy, Chapter 1", in The Epilepsies Etiologies and Prevention, 1999 pp. 1-11.
	A11	V. E. Tyler et al., Pharmacognosy, 9th ed. (Lea and Febiger 1988), pp.456-494.
	A12	H. A. Hare et al., The National Standard Dispensatory, 1905, pp. 93, 94, 159, 160, 169, 256, 642, 692-694, 766, 767, 1031, 1383, 1384, 1426, 1479, 1480, 1571, 1572, 1619-20, 1631-33, 1661-62.

EXAMINER

DATE CONSIDERED

6/04

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

085747/0139

SERIAL NO.

09/258,862
10/624344

OPI INFORMATION DISCLOSURE CITATION

NOV 8 4 2003

(Use several sheets if necessary)

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
------------------	-----	-----------------	------	------	-------	-----------	----------------------------

FOREIGN PATENT DOCUMENTS

--	--	--	--	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A13	D. Hoffman, The Herbal Handbook: A User's Guide to Medical Herbalism, pp. 38, 39, 83 and 84, 1989, (Healing Arts Press).
	A14	Millspaugh, American Medicinal Plants, an illustrated and descriptive guide to the American Plants used as Homeopathic Remedies, pp. 622-626 (Dover 1974).
	A15	Duke, "CRC Handbook of Medicinal Herbs", CRC Press, 1985, p. 557.
	A16	D. Albe-Fessard et al., "Comparison of Different Animal Models of Chronic Pain" in 13 Advances in Pain Research, Mechanisms and Structure, 4 th Ed., 1992, pp. 11-27.
	A17	M. Grieve, A Modern Herbal, pp. 35-40, 265-276, 381, 382, 411-415, 744-746, 781, 782, 824-830, Hafner, 1959.
	A18	R. G. Fariello et al., "Valproic Acid – Mechanisms of Action" in Antiepileptic Drugs (4 th Ed.), pp. 581-588, Raven Press, 1995.
	A19	T. Nogrady, Medicinal Chemistry: A Biochemical Approach" (2 nd Ed.) pp. 225-239 (Oxford University Press) 1988.
	A20	J. J. Cereghino et al., "Introduction" in Antiepileptic Drugs, 4 th Ed., pp. 1-11, (Raven Press), 1995.
	A21	R. H. Levy et al., "General Principles – Drug Absorption, Distribution, and Elimination", in Antiepileptic Drugs, 4 th Ed., pp. 13-30, Raven Press, 1995.
	A22	H. S. White et al., "Experimental Selection, Quantification, and Evaluation of Antiepileptic Drugs", in Antiepileptic Drugs, 4 th Ed., pp. 99-110, Raven Press, 1995.
	A23	A. S. Waters, "Circaedian Rhythm of the Restless Legs", Session No. 30, Sleep Disorders, Restless Legs Syndrome, Neurology Supp. 1995, p. A285.

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED
----------	--------------------	-----------------

6/04

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

085747/0139

SERIAL NO. 10/614344
09/258,882

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

NOV 06 2003

O I P
INFORMATION DISCLOSURE CITATION
Use several sheets if necessary)

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
------------------	-----	-----------------	------	------	-------	-----------	----------------------------

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
--	-----	-----------------	------	---------	-------	-----------	-------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A24	J. C. Ballenger et al., "Kindling as a Model for Alcohol Withdrawal Syndromes", Brit. J. Psychiat. Vol. 133, pp. 1-14, 1978.					
	A25	L. J. Bertman et al., "Comparison of the antinociceptive and antispastic action...spinal rats", Brain Res. 684, pp. 8-18, 1995.					
	A26	D. Blumer et al., "Indications for Carbamazepine in Mental Illness: Atypical Psychiatric Disorder or Temporal Lobe Syndrome?", Compre. Psych., Vol. 28:2, 1988, pp. 108-122.					
	A27	U. Bojic et al., "Further Branching of Valproate-Related Carboxylic Acids Reduces...Effect", Chem. Res. Toxicol., Vol. 9, 1996, pp. 866-870.					
	A28	C. K. Chai, "Influence of Aminooxyacetic Acid...Defect in the Mouse", Proc. Soc. Exptl. Biol. Med. Vol. 109, pp 491-495, 1962.					
	A29	B. Costall et al., "Stereotyped Behavior Patterns and Hyperactivity Induced by Amphetamine and...Mesolimbic Nuclei", Brain Research, Vol. 123, pp. 89-111, 1977.					
	A30	S. L. Dewey et al., "A Pharmacologic Strategy for the Treatment of Nicotine Addiction", Synapse Vol. 31, pp. 76-86, 1999.					
	A31	M. A. Dichter et al., "New Antiepileptic Drugs", Drug Therapy, Vol. 334:24, pp. 1583-1590, 1996.					
	A32	N. W. Dunham et al., "A Note on a Simple Apparatus for Detecting Neurological Deficit in Rats and Mice", J. Am. Pharm. Assn. Vol. 46:3, pp. 208-209, 1957.					
	A33	H. M. Ernrich et al., "The Use of Sodium Valproate, Carbamazepine and Oxcarbazepine in Patients with Affective Disorders", J. Affective Disorders, Vol. 8, pp. 243-250, 1985.					
	A34	D. A. Evans et al., "The Asymmetric Synthesis of α -Hydrazino Acid Derivatives...Esters", Tetrahedron, Vol. 44:17, pp. 5525-5540, 1988.					

EXAMINER

DATE CONSIDERED

6/04

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

085747/0139

SERIAL NO. 10/614,344
09/258,882

APPLICANT

Linda D. Artman et al.

O I P INFORMATION DISCLOSURE CITATION

NOV 04 2003

(Use several sheets if necessary)

FILING DATE

3/01/1999

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

--	--	--	--	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A35	A. Fadel, "Optically Active Cyclopropanols by Samarium (II) Iodide Induced Intramolecular Reductive Cyclisation...Amides." <i>Tetrahedron</i> , Vol. 5:4, pp. 531-534, 1994.
	A36	M. D. Ginsberg et al., "Rodent Models of Cerebral Ischemia", <i>Stroke</i> , Vol. 20:12, pp. 1627-1642, 1989.
	A37	G. V. Goddard et al., "A Permanent Change in Brain Function Resulting from Daily Electrical Stimulation", <i>Exp. Neurology</i> , Vol. 25, pp. 295-330, 1969.
	A38	J. Halikas et al., <i>Lancet</i> 18:623-624, 1989.
	A39	J. Hao et al., "Depression of the flexor reflex by systemic morphine increases in chronically spinalized rats", <i>Euro. J. Pharmacology</i> , Vol. 191, pp. 407-416, 1990.
	A40	R. Hauck et al., "The Enantiomers of Valproic Acid...Highly Stereoselective Teratogenicity in Mice", <i>Pharm. Research</i> , Vol. 9:7, 1992, pp. 850-855.
	A41	R. Hering et al., "Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus Placebo", <i>Cephalgia</i> , Vol. 12, pp. 81-84, 1992.
	A42	R. Hering et al., "Sodium valproate in the treatment of cluster headache: an open clinical trial", <i>Cephalgia</i> , Vol. 9, pp. 195-198, 1989.
	A43	A. J. Hunter et al., "Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs?", <i>Trends. Pharmacol. Sci.</i> , Vol. 16, pp. 123-128, 1996.
	A44	S. Irwin, "Comprehensive Observational Assessment...Physiologic State of the Mouse", <i>Psychopharm.</i> Vol. 13, pp. 222-257, 1968.
	A45	J. Jolkkonen et al., "Seizure-induced damage to the hippocampus is prevented by modulation of the GABAergic system", <i>Neuroreport</i> Vol. 7, pp. 2031-2035, 1996.

EXAMINER

DATE CONSIDERED

6/04

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET N

085747/0139

SERIAL NO.

10/614344
99/258,882

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

NOV 04 2003

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

--	--	--	--	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A46	P. E. Keane et al., "The effects of Analogues of Valproic Acid on Seizures induced by Pentylenetetrazol and GABA Content in Brain of Mice", Neuropharm. Vol 22:7, pp. 875-879, 1983.
	A47	P. E. Keane et al., "Effect of Valproate on Brain GABA: Comparison with Various Medium Chain Fatty Acids", Pharma. Res. Comm. Vol. 17:6, pp. 547-555, 1985.
	A48	W. S. Lee et al., "Peripheral GABA receptor-mediated... and trigeminal stimulation", British J. Pharm. Vol 116, pp. 1661-1667, 1995.
	A49	L. Lin et al., "Valerian-Derived Sedative Agents... Selective INEPT Nuclear Magnetic Resonance Technique", Pharm. Res. Vol. 8:9, pp. 1094-1102.
	A50	W. Loscher et al., "Pharmacological Evaluation of Various Metabolites and Analogues of Valproic Acid", Neuropharm. Vol. 24:5, pp. 427-435, 1985.
	A51	N. T. Mathew et al., "Valproate in the Treatment of Persistent Chronic Daily Headache. An Open Label Study", Headache, Vol. 31, pp. 71-74, 1991.
	A52	T. Matsuyama et al., "Hilar Somatostatin Neurons are More Vulnerable to an Ischemic Insult Than CA1 Pyramidal Neurons", J. Cerebral Blood Flow and Metab., Vol. 13, pp. 229-234, 1993.
	A53	Nau et al., "Valproic Acid Teratogenesis", Atlas Sci. Pharm. Vol. 69. Pp. 52-56, 1987.
	A54	H. Nau, "Valproic Acid Teratogenicity in Mice after Various Administration and Phenobarbital Pretreatment... Implicated as Teratogen", Fund. And Appl. Toxic., Vol. 6, pp. 662-668, 1986.
	A55	H. Nau et al., "Weak acids may act as teratogens by accumulating in the basic milieu of the early Mammalian embryo", Nature, Vol. 323, pp. 276-278, 1986.
	A56	H. Nau et al., "Pharmacologic Evaluation of Various Metabolites and Analogs of Valproic Acid: Teratogenic Potencies in Mice", Fund and Applied Toxicology, Vol. 6, pp. 669-676, 1986.

EXAMINER

DATE CONSIDERED

6/04

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

085747/0139

SERIAL NO.

10/6/94 344
09/25/8821

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

NOV 04 2003



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 085747/0139	SERIAL NO. 10/614 09/258,882 344		
O I P INFORMATION DISCLOSURE CITATION NOV 04 2003 <i>Use several sheets if necessary</i>			APPLICANT	Linda D. Artman et al.			
			FILING DATE 3/01/1999	GROUP ART UNIT 1614			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A68	R. S. Sloviter, "Decreased Hippocampal Inhibition and a Selective Loss of Interneurons in Experimental Epilepsy", Science, Vol. 235, pp. 73-76, 1987.					
	A69	R. Stevens, "The Chemistry of HOP Constituents", Chem. Rev. Vol. 67, pp. 19-71, 1967.					
	A70	M. Swerdlow, "Anticonvulsant Drugs and Chronic Pain", J. Clinical . Neuropharmacology, Vol. 7:1, 1984, pp. 51-82.					
	A71	W. Tang et al., "Fluorinated Analogues as Mechanistic Probes In Valproic Acid Hepatotoxicity: Hepatic... Glutathione Status", Chem. Res. Toxicol. Vol. 8, pp. 671-682, 1995.					
	A72	C. Tober et al., "D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures", Eur. J. Pharmacol. Vol. 15, pp. 163-169, 1996.					
	A73	J. A. Wada et al., "Persistent Seizure Susceptibility and Recurrent Spontaneous Seizures in Kindled Cats", Epilepsia, Vol. 15, pp. 465-478, 1974.					
	A74	J. Wright et al., "The Spastic Mouse", Clin. Orthop. Vol. 253, pp. 12-19, 1990.					
	A75	H. Nau et al., "Valproic Acid-Induced Neural Tube Defects in Mouse...Pharmacokinetic and Possible Mechanisms", Pharm. & Toxicology, Vol. 69, pp. 310-321, 1991.					
EXAMINER 				DATE CONSIDERED 			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							